Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of common shares. The combined gross proceeds are expected to be approximately $2.9 million, with the common shares priced at $0.795 each and the warrants at $0.005 each. The warrants carry an exercise price of $0.84 per share and are exercisable immediately upon issuance.
The transactions are expected to close on or about August 14, 2026, subject to customary closing conditions. Dyadic intends to use the net proceeds, along with its existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. Aegis Capital Corp. is serving as the exclusive placement agent for the offerings.
This capital raise comes at a critical time for Dyadic, as the company continues to develop and commercialize its proprietary Dapibus™ and C1 expression systems. These platforms are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins for the life sciences, food and nutrition, and bio-industrial markets. By securing additional funding, Dyadic aims to advance its mission of providing scalable, non-animal protein production solutions that meet the growing global demand for sustainable products.
The offering underscores investor confidence in Dyadic's technology and market potential. With the additional capital, the company is better positioned to support its ongoing research and development efforts, expand its commercial partnerships, and accelerate the path to market for its innovative protein production platforms. The move is part of a broader strategy to strengthen its financial position and drive long-term growth.
For more information about Dyadic International and its technologies, visit https://dyadic.com/.
